Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000806095 | SCV000946076 | likely benign | Multiple endocrine neoplasia type 4 | 2024-01-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001014630 | SCV001175362 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-10-17 | criteria provided, single submitter | clinical testing | The c.216C>T variant (also known as p.G72G), located in coding exon 1, results from a C to T substitution at nucleotide position 216 of the CDKN1B gene. This nucleotide substitution does not change the amino acid at codon 72. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will result in the creation or strengthening of a novel splice donor site. RNA studies have demonstrated that this alteration results in an incomplete splice defect; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Sema4, |
RCV001014630 | SCV002535473 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-01 | criteria provided, single submitter | curation | |
Baylor Genetics | RCV000806095 | SCV004212423 | uncertain significance | Multiple endocrine neoplasia type 4 | 2023-05-10 | criteria provided, single submitter | clinical testing |